The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas

See, Sharlene Helene C.; Smith, Steven H.; Finkelman, Brian S.; LaBoy, Carissa; Novo, Jorge E; Siziopikou, Kalliopi P.; Blanco, Luis Z.

doi:10.1016/j.prp.2022.154299

Cited by 7 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coexpression of ER and PRAME has not been well studied in cancer, but it is known that PRAME expression in breast cancer more commonly occurs in ER-negative tumors and correlates with more malignant behavior. [55][56][57][58] It is of interest to note that the ER-positive stromal cells in the DICER1-related lesions tended to occur in areas with cyst formation (Figs. 1 and 2).…”

Section: Discussionmentioning

confidence: 99%

“…This was also true for eRMS of ovary and cervix, ciliary body medulloepithelioma, and pineoblastoma (all PRAME-positive, ER-negative). Coexpression of ER and PRAME has not been well studied in cancer, but it is known that PRAME expression in breast cancer more commonly occurs in ER-negative tumors and correlates with more malignant behavior 55–58 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Estrogen Receptor Expression in DICER1-related Lesions is Associated With the Presence of Cystic Components

Thorner,

Chong,

Apellaniz-Ruiz

et al. 2024

American Journal of Surgical Pathology

View full text Add to dashboard Cite

DICER1 tumor predisposition syndrome results from pathogenic variants in DICER1 and is associated with a variety of benign and malignant lesions, typically involving kidney, lung, and female reproductive system. Over 70% of sarcomas in DICER1 tumor predisposition syndrome occur in females. Notably, pediatric cystic nephroma (pCN), a classic DICER1 tumor predisposition syndrome lesion, shows estrogen receptor (ER) expression in stromal cells. There are also renal, hepatic, and pancreatic lesions unassociated with DICER1 tumor predisposition syndrome that have an adult female predominance and are characterized/defined by ER-positive stromal cells. Except for pCN, the expression of ER in DICER1-associated lesions remains uninvestigated. In the present study, ER expression was assessed by immunohistochemistry in 89 cases of DICER1-related lesions and 44 lesions lacking DICER1 pathogenic variants. Expression was seen in stromal cells in pCN and pleuropulmonary blastoma (PPB) types I and Ir, whereas anaplastic sarcoma of kidney and PPB types II and III were typically negative, as were other solid tumors of non-Müllerian origin. ER expression was unrelated to the sex or age of the patient. Expression of ER showed an inverse relationship to preferentially expressed antigen in melanoma (PRAME) expression; as lesions progressed from cystic to solid (pCN/anaplastic sarcoma of kidney, and PPB types I to III), ER expression was lost and (PRAME) expression increased. Thus, in DICER1 tumor predisposition syndrome, there is no evidence that non-Müllerian tumors are hormonally driven and antiestrogen therapy is not predicted to be beneficial. Lesions not associated with DICER1 pathogenic variants also showed ER-positive stromal cells, including cystic pulmonary airway malformations, cystic renal dysplasia, and simple renal cysts in adult kidneys. ER expression in stromal cells is not a feature of DICER1 perturbation but rather is related to the presence of cystic components.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Estrogen Receptor Expression in DICER1-related Lesions is Associated With the Presence of Cystic Components

Thorner,

Chong,

Apellaniz-Ruiz

et al. 2024

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…A high frequency of PRAME expression is reported in malignant melanomas, myxoid liposarcomas, synovial sarcomas, neuroblastomas, and thymic squamous cell carcinomas [13,[25][26][27][28]30,36]. PRAME expression is more frequently noted in non-epithelial malignant tumors than in epithelial malignant tumors (Table 3); moreover, its expression has been noted in various types of non-epithelial and epithelial malignant tumors at low-to-intermediate levels (Table 3) [13,25,[36][37][38][39][40][41][42][43][44][45][46][47][48]. Importantly, no PRAME expression was reported in some types of malignant tumor, such as prostate cancer, gastric cancer, and gastrointestinal stromal tumors [13].…”

Section: Discussionmentioning

confidence: 99%

“…Thymic cancer High [13,30] Lung cancer Intermediate-high [13,25,40,41] Breast cancer Intermediate-high [13,25,[42][43][44] Ovarian cancer Intermediate [13,25,45,46] Renal cell carcinoma Low-intermediate [13,25,29] Colorectal cancer Low-intermediate [13,47] Hepatocellular carcinoma Low [13,48] Pancreatic cancer Low [13] PRAME, preferentially expressed antigen in melanoma.…”

Section: Epithelial Tumorsmentioning

confidence: 99%

Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract

Fujii,

Ishida,

Komura

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Carcinoma in situ (CIS) of the urinary tract comprises 1–3% of all urothelial malignancies and is often a precursor to muscle-invasive urothelial carcinoma (UC). This study aimed to examine the expression profiles of preferentially expressed antigen in melanoma (PRAME), a cancer/testis antigen, and assess its diagnostic and therapeutic applications in CIS, given that its expression in UC has been minimally studied and has not yet been analyzed in CIS. We selected consecutive patients with CIS who underwent biopsy and/or transurethral tumor resection at the Osaka Medical and Pharmaceutical University Hospital. Immunohistochemical staining for PRAME and p53 was performed. Overall, 53 patients with CIS (6 females and 47 males) were included. Notably, PRAME expression was observed in 23 of the 53 patients (43.4%), whereas it was absent in the non-neoplastic urothelial epithelium. Furthermore, no correlation was found between PRAME expression and aberrant p53 expression. Therefore, PRAME expression may serve as a useful marker for CIS of the urinary tract. Furthermore, PRAME may be a candidate for the novel therapeutic target for standard treatment-refractory CIS patients.

show abstract

“…The Notch, Wnt/β-catenin, and Hedgehog signaling pathways have also been reported to be important contributors to incidences of TNBC[ 30 - 32 ]. Nevertheless, there are different opinions on the key mechanisms of TNBC[ 33 , 34 ], and many molecular events believed to be related to TNBC need more scientific attention.…”

Section: Introductionmentioning

confidence: 99%

Bibliometric analysis of phosphoglycerate kinase 1 expression in breast cancer and its distinct upregulation in triple-negative breast cancer

Chen,

Li,

et al. 2024

World J Clin Oncol

View full text Add to dashboard Cite

BACKGROUND Phosphoglycerate kinase 1 (PGK1) has been identified as a possible biomarker for breast cancer (BC) and may play a role in the development and advancement of triple-negative BC (TNBC). AIM To explore the PGK1 and BC research status and PGK1 expression and mechanism differences among TNBC, non-TNBC, and normal breast tissue. METHODS PGK1 and BC related literature was downloaded from Web of Science Core Collection Core Collection. Publication counts, key-word frequency, cooperation networks, and theme trends were analyzed. Normal breast, TNBC, and non-TNBC mRNA data were gathered, and differentially expressed genes obtained. Area under the summary receiver operating characteristic curves, sensitivity and specificity of PGK1 expression were determined. Kaplan Meier revealed PGK1’s prognostic implication. PGK1 co-expressed genes were explored, and Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Disease Ontology applied. Protein-protein interaction networks were constructed. Hub genes identified. RESULTS PGK1 and BC related publications have surged since 2020, with China leading the way. The most frequent keyword was “Expression”. Collaborative networks were found among co-citations, countries, institutions, and authors. PGK1 expression and BC progression were research hotspots, and PGK1 expression and BC survival were research frontiers. In 16 TNBC vs non-cancerous breast and 15 TNBC vs non-TNBC datasets, PGK1 mRNA levels were higher in 1159 TNBC than 1205 non-cancerous breast cases [standardized mean differences (SMD): 0.85, 95% confidence interval (95%CI): 0.54-1.16, I ² = 86%, P < 0.001]. PGK1 expression was higher in 1520 TNBC than 7072 non-TNBC cases (SMD: 0.25, 95%CI: 0.03-0.47, I ² = 91%, P = 0.02). Recurrence free survival was lower in PGK1-high-expression than PGK1-low-expression group (hazard ratio: 1.282, P = 0.023). PGK1 co-expressed genes were concentrated in ATP metabolic process, HIF-1 signaling, and glycolysis/gluconeogenesis pathways. CONCLUSION PGK1 expression is a research hotspot and frontier direction in the BC field. PGK1 may play a strong role in promoting cancer in TNBC by mediating metabolism and HIF-1 signaling pathways.

show abstract

The role of PRAME and NY-ESO-1 as potential therapeutic and prognostic biomarkers in triple-negative breast carcinomas

Cited by 7 publications

References 16 publications

Estrogen Receptor Expression in DICER1-related Lesions is Associated With the Presence of Cystic Components

Estrogen Receptor Expression in DICER1-related Lesions is Associated With the Presence of Cystic Components

Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract

Bibliometric analysis of phosphoglycerate kinase 1 expression in breast cancer and its distinct upregulation in triple-negative breast cancer

Contact Info

Product

Resources

About